2020 ASCO Follow up on Adjuvant Therapy in High-risk Melanoma: Does Pembro Provide Sustained RFS Benefit in Resected Stage III Melanoma? Is There a Long-term Survival Benefit With Dabrafenib + Trametinib in BRAF+ Disease?

96 views
July 22, 2020
0 Comments
Login to view comments. Click here to Login